DeFi Study Establishes Role of Nirogacestat in Desmoid Tumors
Richard F. Riedel, MDProfessor of MedicineDuke University School of MedicineMember, Duke Cancer InstituteDurham, NCThis is part 2 of a 2-part...
Desmoid
Nirogacestat Provides Long-Term Benefits in Desmoid Tumors
Nirogacestat in Desmoid Tumors | Image Credit: © Katsyarina – stock.adobe.comLong-term treatment with nirogacestat (Ogsiveo) was linked with an improved...
Evaluating Survival, Long-Term Use of Nirogacestat in Desmoid Tumors
Nam Quoc Bui, MDClinical Associate Professor of MedicineStanford Cancer InstituteStanford, CAPlease discuss the design of trial of nirogacestat (Ogsiveo) for...
Nirogacestat in patients with desmoid tumors and mutations of adenomatous polyposis coli (APC)
In the phase 3 DeFi trial (NCT03785964), niro demonstrated significant improvement vs placebo (pbo) in progression-free survival (PFS; HR 0.29...
EMA Validates Marketing Application for Nirogacestat in Desmoid Tumors
"These results support that nirogacestat will be a practice-changing therapy if approved by the EMA," according to Bernd Kasper, MD,...
Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors
Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid TumorsPatients with desmoid tumors experienced significant and clinically meaningful reductions in...
SpringWorks completes submission of NDA to US FDA for nirogacestat to treat desmoid tumours
The NDA submission is being reviewed under the FDA's Real-Time Oncology Review (RTOR) programme and includes data from the phase...
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics, Inc.STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused...
‘Potential New Standard’ for Progressing Desmoid Tumors
PARIS -- Progression-free survival (PFS) was significantly prolonged in patients with progressing desmoid tumors treated with an investigational gamma secretase...